ClinicalTrials.gg
RecruitingNCT06962800PROMINENTUpdated Nov 9, 2026

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

A Phase 3 interventional study of Felzartamab and Tacrolimus in Primary Membranous Nephropathy, sponsored by Biogen. Recruiting at 117 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 9, 20265 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.

Planned enrollment
6th of 50
180 · median 77
Started
2025
with 7 others
Phase 3
9 of 60
4 open now
Primary completion
2030-01
later than 36 of 36 live
Registered
44th of 60
by date

Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 6th largest by planned enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2025, is one of 9 in phase 3, reaches primary completion later than 36 of the 36 other live ones, and was the 44th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 13 (32%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Glomerulonephritis, Membranous with a site in China, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type of antibody that mistakenly targets and attacks the body's own tissues. Glomeruli are the filters of the kidney that remove waste and extra fluid from the body. In PMN, the build-up of autoantibodies in the glomeruli causes damage to the kidneys.

Kidney damage can lead to too much protein and blood leaking into the urine. High levels of protein in the urine, called proteinuria, are common in people with PMN. Symptoms of PMN can include swelling in the legs and body, tiredness, and high blood pressure. If left untreated, PMN can eventually lead to kidney failure.

In this study, researchers will learn more about how a study drug called felzartamab affects people with PMN. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce autoantibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works compared to a drug called tacrolimus. Tacrolimus is another drug given to people with PMN and kidney disease.

The main question that researchers want to answer is:

  • How many participants achieve a complete response after 104 weeks of treatment?
  • A complete response means that their urine protein levels decrease to a low level and their kidney function remains stable.

Researchers will also learn about:

  • How long it takes before the participants' disease gets worse
  • How long the participants' urine protein levels stay low
  • How many participants develop antibodies against felzartamab in the blood?
  • How many participants achieve a complete response after 76 weeks of treatment
  • How many participants have medical problems during the study
  • How felzartamab is processed by the body
  • How felzartamab affects participants' tiredness and overall physical health

The study will be done as follows:

  • Participants will be screened to check if they can join the study. This may take up to 42 days.
  • Participants will be randomized to receive either felzartamab as intravenous (IV) infusions or tacrolimus, taken orally as tablets.
  • If participants have worsening kidney function or worsening proteinuria, or if their PMN relapses, or if they show no signs of improvement in their PMN, they will have a chance to receive rescue treatment.
  • If a participant stops treatment early, there will be follow-up visits every 12 weeks until they reach Week 104.
  • In total, participants will have up to 23 study visits. Participants who do not need rescue treatment will stay in the study for up to 104 weeks. Participants who need rescue treatment will stay in the study for up to 156 weeks.
Read the detailed description

The primary objective of the study is to assess the efficacy of felzartamab compared to tacrolimus in participants with PMN in achieving complete remission (CR) of proteinuria. The secondary objectives of the study are to evaluate the efficacy of felzartamab through additional clinical endpoints and timepoints, to assess the impact of felzartamab on serum anti-phospholipase A2 receptor (PLA2R) antibodies and patient-reported outcomes, and to assess the safety, pharmacokinetics (PK) and immunogenicity of felzartamab.

03

Conditions studied

  • Primary Membranous Nephropathy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosed with PMN in need of IST according to the Investigator's clinical judgment. The diagnosis of PMN must be documented with the presence of nephrotic syndrome, and hypoalbuminemia, and confirmed with a kidney either during Screening or within 5 years of signing the form (ICF) [see kidney biopsy exception below for participants positive for anti-PLA2R antibodies]. For these participants, the biopsy report with redacted protected health information must be available to be reviewed by the Sponsor or an independent nephropathologist. If the participant requires a kidney biopsy during Screening, medical monitor approval must be obtained, and all other eligibility criteria should be reviewed to ensure that the participant is otherwise eligible prior to performing the kidney biopsy.

    a. Kidney biopsy exception for anti-PLA2R antibody positive participants: Participants who are positive for anti-PLA2R antibodies at Screening and have not had a kidney biopsy performed within 5 years of signing the ICF may be eligible for the study without undergoing a kidney biopsy based on medical monitor review of screening tests confirming normal estimated (eGFR), presence of nephrotic syndrome, hypoalbuminemia, positive anti-PLA2R antibody test (defined as an anti-PLA2R antibody titer ≥ 20 RU/mL), and documentation provided by the Investigator that the work-up for secondary causes of membranous nephropathy (MN) was negative with no identifiable secondary causes.

  • Meets one of the following:

    1. Newly diagnosed PMN, defined as having never received IST for PMN in the past.
    2. PMN, defined as documented achievement of CR or partial remission (PR) after treatment with an IST for PMN followed by reappearance of nephrotic range proteinuria (urine protein to creatinine ratio [UPCR] ≥ 3.0 gram per gram [g/g] from a 24-hour urine collection or proteinuria ≥ 3.5 gram per 24 hour [g/24 h]).
  • Participants must be on the maximally approved dose or maximally tolerated dose of at least one renin-angiotensin-aldosterone system (RAAS) inhibition therapy (e.g. angiotensin-converting enzyme inhibitor [ACEI], angiotensin receptor blocker [ARB], and/or mineralocorticoid receptor antagonists [MRA]) for at least 4 weeks prior to Screening. Participants not on the maximally approved dose of RAAS inhibition may be enrolled provided there is documented intolerance to maximal RAAS inhibition (e.g., angioedema, development of postural hypotension, lightheadedness, hyperkalemia, etc). Participants on MRA therapy alone at Screening must have documented prior intolerance of ACEI or ARB therapy. Participants who do not tolerate ACEI or ARB therapy are not required to start MRA therapy prior to Screening.
  • A UPCR of ≥ 3.0 g/g (as determined by a 24-hour urine collection) or total proteinuria ≥ 3.5 g/24 h (as determined by a 24-hour urine collection) at Screening after best supportive care for at least 4 weeks prior to signing the ICF.

Key Exclusion Criteria:

  • Secondary cause of MN (e.g., , medications, systemic lupus erythematosus [SLE], , , etc).
  • Severe renal impairment is defined as an eGFR ≤ 30 mL/min/1.73m\^2 at Screening or including the need for dialysis or renal replacement therapy.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Open-Label Treatment Phase

    Participants will receive several intravenous (IV) doses of felzartamab or oral tacrolimus in the Open-Label Treatment Phase.

    Drug: Felzartamab · Drug: Tacrolimus

  • Experimental
    Non-Responder Treatment Phase

    Participants initially randomized to felzartamab or tacrolimus who meet rescue criteria may receive regional standard of care immunosuppressive therapy (IST) per Investigator discretion or several IV doses of felzartamab, respectively, in the Non-Responder Treatment Phase.

    Drug: Felzartamab · Drug: Standard of Care IST

Interventions

  • Administered intravenously

    Also known as: MOR202, MOR03087, TJ202, BIIB148, HIB202

  • Administered orally

  • DrugStandard of Care IST

    Administered intravenously and orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Achieve Complete Remission (CR) at Week 104

    Time frame: Week 104

Secondary outcomes

  1. Percentage of Participants who Achieve Overall Remission (OR), Defined as CR or Partial Remission (PR) at Week 104

    Time frame: Week 104

  2. Percentage of Participants who Achieve CR at Week 76

    Time frame: Week 76

  3. Duration of CR

    Time frame: Baseline up to Week 156

  4. Percentage of Participants With a Baseline Anti-Phospholipase A2 Receptor (PLA2R) Autoantibody Titer Greater Than 50 Relative Unit per Milliliter (RU/mL) who Achieve an OR at Week 76 and at Week 104

    Time frame: Weeks 76 and 104

  5. Time to Disease Worsening

    Time frame: Baseline up to Week 156

  6. Time to a Sustained Reduction in eGFR of ≥ 30% From Baseline

    Time frame: Baseline up to Week 104

  7. Absolute Change in Anti-PLA2R Autoantibody Titer in Participants Positive for Anti-PLA2R at Baseline

    Time frame: Baseline up to Week 156

  8. Change From Baseline in the Patient Reported Outcome Measurement Information System (PROMIS) Fatigue Scale at Week 104

    Time frame: Week 104

  9. Change From Baseline in PROMIS Global Assessment of Physical Health Scale at Week 104

    Time frame: Week 104

  10. Number of Participants With Treatment Emergent Adverse Event (TEAE), Serious Adverse Event (SAE) and Adverse Events of Special Interest (AESIs)

    Time frame: From first dose of study drug up to end of follow-up (up to Week 156)

  11. Felzartamab Serum Concentrations Over Time

    Time frame: Predose and at multiple timepoints post dose up to Week 156

  12. Number of Participants With Anti-Drug Antibodies (ADAs) Against Felzartamab

    Time frame: Predose and at multiple timepoints post dose up to Week 156

07

Study locations

116 of 117 sites recruiting
  • Apogee Clinical Research, LLC
    Huntsville, Alabama 35805-4104, United States
    Recruiting
    • · Contact256-533-4626
    • Michael Quadrini · Principal investigator
  • The Nephrology Group, Inc. - Fresno
    Fresno, California 93720-2989, United States
    Recruiting
    • · Contact559-228-6600
    • Yangming Cao · Principal investigator
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
    Recruiting
    • · Contact323-725-0051
    • Mohamed El-Shahawy · Principal investigator
  • UCLA Health Connie Frank Kidney Transplant Center and General Nephrology
    Los Angeles, California 90095-8344, United States
    Recruiting
    • · Contact310-794-5024
    • Anjay Rastogi · Principal investigator
  • UCSF Medical Center
    San Francisco, California 94143-2205, United States
    Recruiting
    • · Contact415-353-7900
    • Christopher Carlos · Principal investigator
  • Stanford University
    Stanford, California 94305-2200, United States
    Recruiting
    • · Contact650-721-4011
    • Fahmeedah Kamal · Principal investigator
  • Henry Ford Hospital- A-Basement Research Pharmacy
    Detroit, Michigan 48202-2608, United States
    Recruiting
    • · Contact313-900-2298
    • Douglas Atchison · Principal investigator
  • Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS
    Pontiac, Michigan 48341, United States
    Completed

    Not enrolling at this site — choose another above.

  • James J Peters Veterans Administration Medical Center - NAVREF - PPDS
    The Bronx, New York 10468, United States
    Recruiting
    • · Contact718-584-9000
    • Chang Xu · Principal investigator
  • ECU Physicians Nephrology and Hypertension
    Greenville, North Carolina 27834, United States
    Recruiting
    • · Contactobir@ecu.edu · 252-744-2545
    • Reginald Obi · Principal investigator
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106-1716, United States
    Recruiting
  • Knoxville Kidney Center, PLLC
    Knoxville, Tennessee 37923-3624, United States
    Recruiting
    • · Contact865-692-3462
    • George Newman · Principal investigator
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37204-3609, United States
    Recruiting
    • · Contact615-936-1179
    • Neil Sanghani · Principal investigator
  • Nephrotex Research Group
    Dallas, Texas 75231-0929, United States
    Recruiting
    • · Contact214-396-4950
    • Sumit Kumar · Principal investigator
  • University of Texas Medical Branch
    League City, Texas 77573, United States
    Recruiting
    • · Contact409-772-2473
    • Shikha Wadhwani · Principal investigator
  • University of Wisconsin School of Medicine and Public Health
    Madison, Wisconsin 53792-0001, United States
    Recruiting
    • · Contact608-265-0631
    • Sarah Panzer · Principal investigator
  • Organización Médica de Investigación
    Buenos Aires, C1015ABO, Argentina
    Recruiting
  • CINME S.A. - Centro de Investigaciones Metabólicas
    Buenos Aires, C1056ABI, Argentina
    Recruiting
    • · Contact548889000000
    • Fernando Halac · Principal investigator
  • Hospital Italiano de Buenos Aires
    Buenos Aires, C1199ABB, Argentina
    Recruiting
    • · Contact541150000000
    • Carlos Varela · Principal investigator
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Buenos Aires, C1425, Argentina
    Recruiting
    • · Contact541134723300
    • Mria Smuclir Quevedo · Principal investigator
  • Clínica Privada Vélez Sarsfield
    Córdoba, X5016KET, Argentina
    Recruiting
    • · Contact5403514432121
    • Rafael Maldonado · Principal investigator
  • Concord Hospital
    Concord, New South Wales 2138, Australia
    Recruiting
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
    Recruiting
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
    Recruiting
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Recruiting
  • Townsville Hospital
    Douglas, Queensland 4814, Australia
    Recruiting
  • Royal Brisbane and Women s Hospital
    Herston, Queensland 4006, Australia
    Recruiting
  • Gold Coast University Hospital
    Southport, Queensland 4215, Australia
    Recruiting
  • Griffith University Clinical Trial Unit
    Southport, Queensland 4215, Australia
    Recruiting
  • Monash Health
    Clayton, Victoria 3168, Australia
    Recruiting
  • Sunshine Hospital - Australia
    St Albans, Victoria 3021, Australia
    Recruiting
  • Santa Casa de Misericórdia de Belo Horizonte
    Belo Horizonte, Minas Gerais 30150-221, Brazil
    Recruiting
    • · Contact55319422796
    • Pedro Augusto Macedo de Souza · Principal investigator
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90560-030, Brazil
    Recruiting
    • · Contact555134000000
    • Cristina Karohl · Principal investigator
  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)
    Porto Alegre, Rio Grande do Sul 90610-001, Brazil
    Recruiting
  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo
    Ribeirão Preto, São Paulo 14051-140, Brazil
    Recruiting
    • · Contact551640000000
    • Gustavo Misiara · Principal investigator
  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
    São José do Rio Preto, São Paulo 15090-000, Brazil
    Recruiting
    • · Contact551732000000
    • Fernanda Cristina Camelo Sanches · Principal investigator
  • Hospital Alemao Oswaldo Cruz (HAOC)
    São Paulo, 01327-001, Brazil
    Recruiting
    • · Contact551135000000
    • Victor Sato · Principal investigator
  • Centro de Pesquisa Clínica de Nefrologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, 05304-000, Brazil
    Recruiting
    • · Contact551127000000
    • Irene Noronha · Principal investigator
  • Vancouver Coastal Health Research Institute
    Vancouver, British Columbia V5Z 1M9, Canada
    Recruiting
    • · Contact6048754323
    • Sean Barbour · Principal investigator
  • London Health Sciences Centre - Victoria Hospital
    London, Ontario N6A 5W9, Canada
    Recruiting
  • Fu Yang People's Hospital - South Campus
    Fuyang, Anhui 236006, China
    Recruiting
  • Beijing Tsinghua Changgung Hospital
    Beijing, Beijing Municipality 102218, China
    Recruiting
  • Peking University First Hospital - Changqiao Campus
    Xichengqu Beijing, Beijing Municipality 100034, China
    Recruiting
  • Zhongshan Hospital Xiamen University
    Xiamen, Fujian 361004, China
    Recruiting
  • Gansu Provincial Hospital
    Lanzhou, Gansu 730000, China
    Recruiting
  • Lanzhou University Second Hospital
    Lanzhou, Gansu 730030, China
    Recruiting
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong 510280, China
    Recruiting
  • Shenzhen Hospital of Southern Medical University
    Shenzhen, Guangdong 510086, China
    Recruiting
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
    Recruiting
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
    Recruiting
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
    Recruiting
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou 550004, China
    Recruiting
  • The Second Hospital of Hebei Medical University - Main
    Shijiazhuang, Hebei 50000, China
    Recruiting
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei 50031, China
    Recruiting
  • Daqing Oilfield General Hospital
    Daqing, Heilongjiang 163001, China
    Recruiting
  • The First Affiliated Hospital of Henan Science and Technology University - Jinghua Campus
    Luoyang, Henan 471003, China
    Recruiting
  • Yichang Central People's Hospital - Wujiagang Campus
    Yichang, Hubei 443003, China
    Recruiting
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
    Recruiting
  • Yueyang People Hospital
    Yueyang, Hunan 414000, China
    Recruiting
  • The Second Affiliated Hospital of Nanjing Medical University - Main Campus
    Nanjing, Jiangsu 210011, China
    Recruiting
  • The Second Affiliated Hospital of Xian Jiaotong University
    Xi'an, Shaanxi 710004, China
    Recruiting
  • The First Affiliated Hospital of Xian Jiaotong University
    Xi'an, Shaanxi 710061, China
    Recruiting
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Recruiting
  • The Second Hospital of Shandong University
    Jinan, Shandong 250033, China
    Recruiting
  • The Affiliated Hospital of Qingdao University - Xihaian Campus
    Qingdao, Shandong 266555, China
    Recruiting
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
    Recruiting
  • Ruijin Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
    Recruiting
  • Huashan Hospital Fudan University
    Shanghai, Shanghai Municipality 200040, China
    Recruiting
  • Shanghai General Hospital - North Campus
    Shanghai, Shanghai Municipality 200080, China
    Recruiting
  • Sichuan Academy of Medical Sciences Sichuan Provincial People Hospital
    Chengdu, Sichuan 610072, China
    Recruiting
  • The First Affiliated Hospital, Zhejiang University School of Medicine - Qingchun Campus - PPDS
    Hangzhou, Zhejiang 310003, China
    Recruiting
  • The Second Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
    Recruiting
  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine - Qingchun Campus
    Hangzhou, Zhejiang 310016, China
    Recruiting
  • The First Affiliated Hospital of Ningbo University - Yuehu Campus
    Ningbo, Zhejiang 315010, China
    Recruiting
  • Osmania General Hospital
    Hyderabad, Andhra Pradesh 500012, India
    Recruiting
  • Nizams Institute of Medical Sciences
    Hyderabad, Andhra Pradesh 500082, India
    Recruiting
  • Manipal Hospital Bangalore
    Bangalore, Karnataka 560017, India
    Recruiting
  • M.S. Ramaiah Medical College and Hospital
    Bangalore, Karnataka 560054, India
    Recruiting
  • Noble Hospital
    Pune, Maharashtra 411013, India
    Recruiting
  • Max Super Speciality Hospital - Saket
    New Delhi, National Capital Territory of Delhi 110017, India
    Recruiting
  • Sir Ganga Ram Hospital
    New Delhi, National Capital Territory of Delhi 110060, India
    Recruiting
  • Sanjay Gandhi Postgraduate Institute of Medical Sciences
    Lucknow, Uttar Pradesh 226014, India
    Recruiting
  • Regency Health Super Specialty Hospital - Lucknow
    Lucknow, Uttar Pradesh 226022, India
    Recruiting
  • Galaxy Hospital - Varanasi
    Varanasi, Uttar Pradesh 221010, India
    Recruiting
  • Nil Ratan Sircar Medical College and Hospital
    Kolkata, West Bengal 700014, India
    Recruiting
  • Postgraduate Institute of Medical Education & Research (PGIMER)
    Chandigarh, 160012, India
    Recruiting
  • National Hospital Organization Chiba Medical Center Chibahigashi National Hospital
    Chia-shi, Chiba 260-8712, Japan
    Recruiting
  • Juntendo University Urayasu Hospital
    Urayasu-Shi, Chiba 279-0021, Japan
    Recruiting
  • Hokkaido University Hospital
    Sapporo, Hokkaidô 060-8648, Japan
    Recruiting
  • Kagawa University Hospital
    Kita-Gun Uchiko-Cho, Kagawa-ken 761-0793, Japan
    Recruiting
  • The Kitasato Institute Kitasato University Hospital
    Sagamihara-Shi Minami-Ku, Kanagawa 252-0375, Japan
    Recruiting
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
    Recruiting
  • University of Miyazaki Hospital
    Miyazaki, Miyazaki 889-1692, Japan
    Recruiting
  • Niigata University Medical & Dental Hospital
    Niigata, Niigata 951-8520, Japan
    Recruiting
  • Social Medical Corporation Yuuaikai Yuuai Medical Center
    Tomigusuku-Shi, Okinawa 901-0224, Japan
    Recruiting
  • The University of Osaka Hospital
    Suita-Shi, Osaka 565-0871, Japan
    Recruiting
  • Saitama Medical University Hospital
    Iruma-Gun Moroyama-Machi, Saitama 350-0451, Japan
    Recruiting
  • Japanese Red Cross Musashino Hospital
    Musashino-shi, Tokyo 180-8610, Japan
    Recruiting
  • Hospital Raja Permaisuri Bainun
    Perak, Pahang 30450, Malaysia
    Recruiting
  • Hospital Canselor Tuanku Muhriz UKM
    Cheras, WilayahPersekutuan KualaLumpur 56000, Malaysia
    Recruiting

Showing the first 100 of 117 sites across 11 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jan 2030, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 8, 2025
StartActual
May 22, 2025
Primary completionEst.
Jan 28, 2030
CompletionEst.
Jan 17, 2031
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added
Show 5 added (3 China, 1 Japan, 1 South Korea)
  • The First Affiliated Hospital of Ningbo University - Yuehu Campus · Ningbo, China
  • The University of Osaka Hospital · Suita-Shi, Japan
  • Shanghai General Hospital - North Campus · Shanghai, China
  • Sichuan Academy of Medical Sciences Sichuan Provincial People Hospital · Chengdu, China
  • Severance Hospital, Yonsei University Health System · Seoul, South Korea
across 2 updates, Sep 29, 2026 – Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    3 sites added
    Show 3 added (2 China, 1 South Korea)
    • Shanghai General Hospital - North Campus · Shanghai, China
    • Sichuan Academy of Medical Sciences Sichuan Provincial People Hospital · Chengdu, China
    • Severance Hospital, Yonsei University Health System · Seoul, South Korea
    + 1 other change: verification date
  2. Sep 29, 2026
    2 sites added
    Show 2 added (1 China, 1 Japan)
    • The First Affiliated Hospital of Ningbo University - Yuehu Campus · Ningbo, China
    • The University of Osaka Hospital · Suita-Shi, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06962800
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
May 8, 2025
Start date
May 22, 2025
Primary completion
Jan 28, 2030 (estimated)
Completion
Jan 17, 2031 (estimated)
Last update
Nov 9, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion